In a study using the same database that we used, but with a different study design, Chen et al. report a 52% lower risk of composite CV events (HR 0.48; 95% CI, 0.25–0.90; p = 0.0222) in patients with PCa treated with GnRH antagonist than GnRHa, at 12 months; the risk of CV events was not significantly lower in patients who had myocardial infarction, ischemic stroke, or CVD [13]. This evidence concerns the gene GNRH1 and myocardial infarction.